Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Unicycive Therapeutics to post earnings of ($0.13) per share for the quarter.
Unicycive Therapeutics Trading Down 2.2 %
UNCY stock traded down $0.01 during trading on Thursday, hitting $0.65. 959,812 shares of the company's stock were exchanged, compared to its average volume of 1,379,078. The business has a 50-day moving average price of $0.59 and a two-hundred day moving average price of $0.55. The stock has a market capitalization of $67.36 million, a price-to-earnings ratio of -0.67 and a beta of 2.26. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.60.
Analyst Upgrades and Downgrades
UNCY has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Unicycive Therapeutics in a report on Wednesday, January 29th. Benchmark reissued a "speculative buy" rating and issued a $3.00 target price on shares of Unicycive Therapeutics in a report on Friday, November 22nd.
Check Out Our Latest Analysis on UNCY
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
See Also
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
